Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2026, Vol. 31 ›› Issue (7): 885-891.doi: 10.12092/j.issn.1009-2501.2026.07.003
Previous Articles Next Articles
Hangle XIONG1,3(
), Haowen GONG1,3(
), Yuxiu LIU1,2,3,*(
), Jingyi WANG2,3, Yongtian NI2,3, Weiqin LI3
Received:2025-08-10
Revised:2025-09-13
Online:2026-07-26
Published:2026-08-04
Contact:
Yuxiu LIU
E-mail:15901077937@163.com;18205606375@163.com;liu_yuxiu@163.com
CLC Number:
Hangle XIONG, Haowen GONG, Yuxiu LIU, Jingyi WANG, Yongtian NI, Weiqin LI. Sample size re-estimation method based on estimated information time weighting[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(7): 885-891.
| Parameter | Scenarios |
| 2.2(0.2)4.0 | |
| 3.6 | |
| 4(2)10 | |
| Power | 0.9 |
| 0.025 | |
| 0.3(0.1)0.8 |
Table 1 Scenarios set in a Monte-Carlo simulation on the accuracy of conditional power
| Parameter | Scenarios |
| 2.2(0.2)4.0 | |
| 3.6 | |
| 4(2)10 | |
| Power | 0.9 |
| 0.025 | |
| 0.3(0.1)0.8 |
| Parameter | Scenarios |
| For the simulation of test power, take 2.2-4.0; for the simulation of Type I error, take 0 | |
| 3.6 | |
| 4(2)10 | |
| Power | 0.9 |
| α | 0.025 |
| t | 0.3, 0.5, 0.8 |
| f | 1.5, 2, 2.5 |
Table 2 Parameter settings for the sample size re-estimation method in the Monte-Carlo simulation study
| Parameter | Scenarios |
| For the simulation of test power, take 2.2-4.0; for the simulation of Type I error, take 0 | |
| 3.6 | |
| 4(2)10 | |
| Power | 0.9 |
| α | 0.025 |
| t | 0.3, 0.5, 0.8 |
| f | 1.5, 2, 2.5 |
| Power/Type Ⅰ error rate | Average sample size | ||||||||||
| 0.0 | 0.025 | 0.025 | 0.024 | 0.024 | 0.024 | — | — | — | — | — | |
| 2.2 | 0.622 | 0.590 | 0.569 | 0.613 | 0.603 | 283 | 248 | 244 | 260 | 254 | |
| 2.4 | 0.701 | 0.666 | 0.641 | 0.682 | 0.674 | 280 | 245 | 244 | 256 | 250 | |
| 2.6 | 0.765 | 0.727 | 0.704 | 0.744 | 0.735 | 274 | 241 | 244 | 254 | 249 | |
| 2.8 | 0.820 | 0.787 | 0.765 | 0.799 | 0.791 | 265 | 237 | 243 | 251 | 245 | |
| 3.0 | 0.865 | 0.848 | 0.824 | 0.853 | 0.847 | 251 | 233 | 242 | 246 | 241 | |
| 3.2 | 0.890 | 0.879 | 0.858 | 0.883 | 0.876 | 242 | 231 | 239 | 243 | 238 | |
| 3.4 | 0.924 | 0.918 | 0.900 | 0.919 | 0.916 | 232 | 227 | 237 | 239 | 235 | |
| 3.6 | 0.938 | 0.938 | 0.916 | 0.937 | 0.935 | 225 | 225 | 234 | 236 | 232 | |
| 3.8 | 0.953 | 0.956 | 0.943 | 0.955 | 0.951 | 219 | 221 | 233 | 232 | 228 | |
| 4.0 | 0.967 | 0.975 | 0.963 | 0.974 | 0.972 | 214 | 219 | 229 | 229 | 226 | |
Table 3 Power and average sample size after SSR under different CPs
| Power/Type Ⅰ error rate | Average sample size | ||||||||||
| 0.0 | 0.025 | 0.025 | 0.024 | 0.024 | 0.024 | — | — | — | — | — | |
| 2.2 | 0.622 | 0.590 | 0.569 | 0.613 | 0.603 | 283 | 248 | 244 | 260 | 254 | |
| 2.4 | 0.701 | 0.666 | 0.641 | 0.682 | 0.674 | 280 | 245 | 244 | 256 | 250 | |
| 2.6 | 0.765 | 0.727 | 0.704 | 0.744 | 0.735 | 274 | 241 | 244 | 254 | 249 | |
| 2.8 | 0.820 | 0.787 | 0.765 | 0.799 | 0.791 | 265 | 237 | 243 | 251 | 245 | |
| 3.0 | 0.865 | 0.848 | 0.824 | 0.853 | 0.847 | 251 | 233 | 242 | 246 | 241 | |
| 3.2 | 0.890 | 0.879 | 0.858 | 0.883 | 0.876 | 242 | 231 | 239 | 243 | 238 | |
| 3.4 | 0.924 | 0.918 | 0.900 | 0.919 | 0.916 | 232 | 227 | 237 | 239 | 235 | |
| 3.6 | 0.938 | 0.938 | 0.916 | 0.937 | 0.935 | 225 | 225 | 234 | 236 | 232 | |
| 3.8 | 0.953 | 0.956 | 0.943 | 0.955 | 0.951 | 219 | 221 | 233 | 232 | 228 | |
| 4.0 | 0.967 | 0.975 | 0.963 | 0.974 | 0.972 | 214 | 219 | 229 | 229 | 226 | |
| R score and APS | ||||||
| 2.2 | 2.154 | 2.339 | 2.400 | 2.223 | 2.277 | |
| 2.4 | 1.734 | 1.945 | 2.073 | 1.872 | 1.917 | |
| 2.6 | 1.339 | 1.538 | 1.714 | 1.455 | 1.529 | |
| 2.8 | 0.962 | 1.139 | 1.367 | 1.117 | 1.175 | |
| 3.0 | 0.523 | 0.768 | 1.030 | 0.669 | 0.718 | |
| 3.2 | 0.125 | 0.310 | 0.631 | 0.269 | 0.354 | |
| 3.4 | 0.072 | 0.072 | 0.176 | 0.107 | 0.090 | |
| 3.6 | 0.079 | 0.079 | 0.133 | 0.138 | 0.117 | |
| 3.8 | 0.169 | 0.185 | 0.246 | 0.242 | 0.222 | |
| 4.0 | 0.270 | 0.298 | 0.357 | 0.352 | 0.333 | |
| APS | 0.743 | 0.866 | 1.013 | 0.844 | 0.873 | |
Table 4 R score and APS of SSR under different CPs
| R score and APS | ||||||
| 2.2 | 2.154 | 2.339 | 2.400 | 2.223 | 2.277 | |
| 2.4 | 1.734 | 1.945 | 2.073 | 1.872 | 1.917 | |
| 2.6 | 1.339 | 1.538 | 1.714 | 1.455 | 1.529 | |
| 2.8 | 0.962 | 1.139 | 1.367 | 1.117 | 1.175 | |
| 3.0 | 0.523 | 0.768 | 1.030 | 0.669 | 0.718 | |
| 3.2 | 0.125 | 0.310 | 0.631 | 0.269 | 0.354 | |
| 3.4 | 0.072 | 0.072 | 0.176 | 0.107 | 0.090 | |
| 3.6 | 0.079 | 0.079 | 0.133 | 0.138 | 0.117 | |
| 3.8 | 0.169 | 0.185 | 0.246 | 0.242 | 0.222 | |
| 4.0 | 0.270 | 0.298 | 0.357 | 0.352 | 0.333 | |
| APS | 0.743 | 0.866 | 1.013 | 0.844 | 0.873 | |
| 1 | 国家药品监督管理局药品评审中心. 药物临床试验适应性设计指导原则(试行)[EB/OL]. (2021-01-29) [2024-12-10]. https://www.cde.org.cn/ zdyz/domesticinfopage?zdyzIdCODE=4409e51a403a911757af6caf3ecef129. |
| 2 |
Chen YH, DeMets DL, Lan KKG. Increasing the sample size when the unblinded interim result is promising[J]. Stat Med, 2004, 23 (7): 1023- 1038.
doi: 10.1002/sim.1688 |
| 3 |
Denne JS. Sample size recalculation using conditional power[J]. Stat Med, 2001, 20 (17/18): 2645- 2660.
doi: 10.1007/978-3-030-49528-2_28 |
| 4 |
Gao P, Ware JH, Mehta C. Sample size re-estimation for adaptive sequential design in clinical trials[J]. J Biopharmac Stat, 2008, 18 (6): 1184- 1196.
doi: 10.1080/10543400802369053 |
| 5 |
Mehta C, Pocock SJ. Adaptive increase in sample size when interim results are promising: a practical guide with examples[J]. Stat Med, 2011, 30 (28): 3267- 3284.
doi: 10.1002/sim.4102 |
| 6 |
Lachin JM. A review of methods for futility stopping based on conditional power[J]. Stat Med, 2005, 24 (18): 2747- 2764.
doi: 10.1002/sim.2151 |
| 7 | Pong A, Chow SC. Handbook of adaptive designs in pharmaceutical and clinical development [M]. Boca Raton, Florida: CRC Press, 2011: 94-110. |
| 8 |
Glimm E. Comments on ‘Adaptive increase in sample size when interim results are promising: a practical guide with examples’[J]. Stat Med, 2012, 31 (1): 98- 99.
doi: 10.1002/sim.4424 |
| 9 |
Zhu J, Li X, Liu Y. An optimal hybrid approach to calculate conditional power[J]. Stat Biopharmac Res, 2022, 14 (4): 480- 492.
doi: 10.1080/19466315.2022.2063171 |
| 10 |
Jennison C, Turnbull BW. Adaptive sample size modification in clinical trials: start small then ask for more ?[J]. Stat Med, 2015, 34 (29): 3793- 3810.
doi: 10.1002/sim.6575 |
| 11 | Proschan MA, Lan G, Wittes JT. Statistical monitoring of clinical trials: a unified approach [M]. New York: Springer Science Business Media, 2006: 43-60. |
| 12 | Lan KK, Wittes J. The B-value: a tool for monitoring data[J]. Biometrics, 1988, 44 (2): 579- 585. |
| 13 |
Cui L, Hung HM, Wang SJ. Modification of sample size in group sequential clinical trials[J]. Biometrics, 1999, 55 (3): 853- 857.
doi: 10.1111/j.0006-341X.1999.00853.x |
| 14 |
Wang P, Chow SC. Sample size re-estimation in clinical trials[J]. Stat Med, 2021, 40 (27): 6133- 6149.
doi: 10.1002/sim.9175 |
| 15 |
Liu GF, Zhu GR, Cui L. Evaluating the adaptive performance of flexible sample size designs with treatment difference in an interval[J]. Stat Med, 2008, 27 (4): 584- 596.
doi: 10.1002/sim.2998 |
| 16 | Kapadia SR, Makkar R, Leon M, et al. Cerebral embolic protection during transcatheter aortic‐valve replacement [J]. New Engl J Med, 387(2022): 1253-1263. |
| 17 |
Xiong Y, Campbell BCV, Schwamm LH, et al. Tenecteplase for ischemic stroke at 4.5 to 24 hours without Thrombectomy[J]. N Engl J Med, 2024, 391, 203- 212.
doi: 10.1056/NEJMoa2402980 |
| 18 |
Yeh RW, Shlofmitz R, Moses J, et al. Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis: The AGENT IDE Randomized Clinical Trial[J]. JAMA, 2024, 331 (12): 1015- 1024.
doi: 10.1001/jama.2024.1361 |
| [1] | Jingyi WANG, Hangle XIONG, Yuxiu LIU, Yongtian NI, Weiqin LI. Unplanned sample size re-estimation method and its performance evaluation in clinical trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(5): 617-622. |
| [2] | CHENG Junlin, QIU Runze, HU Yunfang, LIU Jianghui, FAN Hongwei . Analysis of an investigation on reasons for subjects screening failure and exploration of influencing factors in clinical trial in healthy volunteersin phase I clinical trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(6): 804-811. |
| [3] | PENG Siqi, HAN Jinghong. Discussion on the key points of clinical trials for FDA-approved CAR-T cell therapy products [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(11): 1578-1584. |
| [4] | LIANG Yuyan, JI Fang, PAN Ying, XU Shiyao, YANG Shu, XU Liang. Analysis and discussion of the common problems found in medical device clinical trials inspection results from 2016 to 2023 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(1): 131-137. |
| [5] | DU Caiying, QUAN Xianghua, SUN Caihong, YUAN Haidan. Research progress of dalpiciclib in treatment of breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(6): 715-720. |
| [6] | ZHOU Xin, WANG Zhi, DU Wenyu, LIU Zihan, LI Ying, DONG Zhanjun. Research progress in clinical trials of new drugs and candidate drugs for type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(10): 1185-1193. |
| [7] | WANG Zhi, ZHOU Xin, HE Xueru, FU Yuhao, XUN Xuejiao, LI Ying, DONG Zhanjun. Clinical research progress of palbociclib in treatment of breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 205-213. |
| [8] | DAI Jiahui, SUN Sijia, XIE Xuefeng. Quality management and indicator system for clinical trials of medical devices [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 51-58. |
| [9] | CHEN Jianfang, LOU Donghua. Design of case report form for oncology clinical trials based on CDASH [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 762-767. |
| [10] | LIU Xing, LU Xiaoran, WU Ying, YU Haitao, WANG Xiaomin. Ethical analysis and countermeasures of artificial intelligence application in clinical trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 322-327. |
| [11] | ZHU Lili, ZHU Xiuxiu, WANG Wenjun, ZHANG Hailin, LIN Li. Clinical trials of inhalation in pediatric population in China [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 178-183. |
| [12] | ZHENG Ying, ZHANG Ling, YAO Li, WANG Qianhe, ZHU Kexiang. Research progress of PARP inhibitors in pancreatic cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 108-115. |
| [13] | SHE Zhihua, CHEN Zhou, LIANG Songyue. Construction of informatization system of drug clinical trials ethical review based on cloud architecture [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1023-1030. |
| [14] | OUYANG Chenxi, HUANG Jie, XIANG Yuxia, WANG Xiaomin. Ethical issues and countermeasures of early phase trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 802-807. |
| [15] | Pazilaiti YASEN, YUAN Hao, LU Hong, ZHENG Ya, WANG Yuping, ZHOU Yongning. Research progress in clinical trials of targeted drugs for gastric cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 454-461. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||